<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02399085</url>
  </required_header>
  <id_info>
    <org_study_id>MOR208C203</org_study_id>
    <nct_id>NCT02399085</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL</brief_title>
  <acronym>L-MIND</acronym>
  <official_title>A Phase II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Lenalidomide Combined With MOR00208 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MorphoSys AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MorphoSys AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multicentre study to characterize the safety and efficacy of the human
      anti CD19 antibody MOR00208 in combination with Lenalidomide in adult subjects with
      relapsed/refractory Diffuse Large B-cell Lymphoma (DLBCL) who have had at least one, but no
      more than three prior systemic regimens and who are not eligible for high dose chemotherapy
      (HDC) with autologous stem-cell transplantation (ASCT) at the time of study entry.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR = complete response [CR] + partial response [PR])</measure>
    <time_frame>1-3 years approximately</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>1-3 years approximately</time_frame>
    <description>DCR = CR + PR + SD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR)</measure>
    <time_frame>1-3 years approximately</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>1-3 years approximately</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>1-3 years approximately</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of LEN combined with MOR00208 according to the frequency and severity of adverse events (AEs)</measure>
    <time_frame>1-3 years approximately</time_frame>
    <description>Safety profile is assessed according to the frequency and severity of adverse events (AEs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potential immunogenicity of MOR00208</measure>
    <time_frame>upto 2 years</time_frame>
    <description>The absolute number and percentage of patients, who develop anti-MOR00208 antibodies, and the results of semi-quantitative anti-MOR00208 antibody titre determinations of confirmed positive sample assessments will be tabulated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of MOR00208</measure>
    <time_frame>upto 2 years</time_frame>
    <description>time to maximum serum concentration [tmax]</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">81</enrollment>
  <condition>Diffuse Large B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment (MOR00208, lenalidomide)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MOR00208 Fc-Optimized Anti-CD19 Antibody, intravenous Infusion, weekly (Cycle 1-3) to bi-weekly (Cycle 4 onwards), 4 weeks cycles, until disease progression or unacceptable toxicity or discontinuation due to any other reason.
Lenalidomide (Revlimid®), PO, daily, 4 weeks cycles, lenalidomide is used 3 of the 4 weeks. Up to 12 cycles in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MOR00208</intervention_name>
    <description>12 mg/kg</description>
    <arm_group_label>Treatment (MOR00208, lenalidomide)</arm_group_label>
    <other_name>MOR208</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>25 mg</description>
    <arm_group_label>Treatment (MOR00208, lenalidomide)</arm_group_label>
    <other_name>CC-5013</other_name>
    <other_name>IMiD-1</other_name>
    <other_name>Revlimid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Major Inclusion Criteria:

          1. Age &gt;18 years

          2. Histologically confirmed diagnosis of DLBCL

          3. Tumour tissue for central pathology review and correlative studies must be provided.

          4. Patients must have:

               -  relapsed and/or refractory disease

               -  at least one bidimensionally measurable, PET positive disease site (transverse
                  diameter of ≥1.5 cm and perpendicular diameter of ≥1.0 cm at baseline)

               -  received at least one, but no more than three previous systemic regimens for the
                  treatment of DLBCL and one therapy line must have included a CD20-targeted
                  therapy

               -  Eastern Cooperative Oncology Group 0 to 2

          5. Patients not considered in the opinion of the investigator eligible, or patients
             unwilling to undergo intensive salvage therapy including ASCT

          6. Patients must meet the following laboratory criteria at screening:

               -  absolute neutrophil count ≥1.5 × 109/L

               -  platelet count ≥90 × 109/L

               -  total serum bilirubin ≤2.5 × ULN or ≤5 × ULN in cases of Glibert's Syndrome or
                  liver involvement by lymphoma

               -  alanine transaminase, aspartate aminotransferase and alkaline phosphatase ≤3 ×
                  ULN or &lt;5 × ULN in cases of liver involvement

               -  serum creatinine clearance ≥60 mL/minute

          7. Females of childbearing potential (FCBP) must:

               -  not be pregnant

               -  refrain from breastfeeding and donating blood or oocytes

               -  agree to ongoing pregnancy testing

               -  commit to continued abstinence from heterosexual intercourse, or agree to use and
                  be able to comply with the use of double-barrier contraception

          8. Males (if sexually active with a FCBP) must

               -  use an effective barrier method of contraception

               -  refrain from donating blood or sperm

          9. In the opinion of the investigator the patients must:

               -  be able and willing to receive adequate prophylaxis and/or therapy for
                  thromboembolic events

               -  be able to understand the reason for complying with the special conditions of the
                  pregnancy prevention risk management plan and give written acknowledgement of
                  this.

        Major Exclusion Criteria:

          1. Patients who have:

               -  other histological type of lymphoma

               -  primary refractory DLBCL

               -  a history of &quot;double/triple hit&quot; genetics

          2. Patients who have, within 14 days prior to Day 1 dosing:

               -  not discontinued CD20-targeted therapy, chemotherapy, radiotherapy,
                  investigational anticancer therapy or other lymphoma specific therapy

               -  undergone major surgery or suffered from significant traumatic injury

               -  received live vaccines.

               -  required parenteral antimicrobial therapy for active, intercurrent infections

          3. Patients who:

               -  were previously treated with CD19-targeted therapy or IMiDs® (e.g. thalidomide,
                  LEN)

               -  have undergone ASCT within the period ≤ 3 months prior to signing the informed
                  consent form.

               -  have undergone previous allogenic stem cell transplantation

               -  have a history of deep venous thrombosis/embolism and who are not willing/able to
                  take venous thromboembolic event prophylaxis during the entire treatment period

               -  concurrently use other anticancer or experimental treatments

          4. Prior history of malignancies other than DLBCL, unless the patient has been free of
             the disease for ≥5 years prior to screening.

          5. Patients with:

               -  positive hepatitis B and/or C serology.

               -  known seropositivity for or history of active viral infection with human
                  immunodeficiency virus (HIV)

               -  CNS lymphoma involvement

               -  history or evidence of clinically significant cardiovascular, CNS and/or other
                  systemic disease that would in the investigator's opinion preclude participation
                  in the study or compromise the patient's ability to give informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sumeet V Ambarkhane, MD</last_name>
    <role>Study Director</role>
    <affiliation>Clinical Program Leader</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Redondo Beach</city>
        <state>California</state>
        <zip>90277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Santa Maria</city>
        <state>California</state>
        <zip>93454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Grand Junction</city>
        <state>Colorado</state>
        <zip>81501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <zip>06856</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Michigan Center</city>
        <state>Michigan</state>
        <zip>48179</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Antwerp</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Kortrijk</city>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Olomouc</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Lyon</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60488</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Nürnberg</city>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Modena</city>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Perugia</city>
        <zip>6132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Roma</city>
        <zip>133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Terni</city>
        <zip>5100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Olsztyn</city>
        <zip>10228</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Opole</city>
        <zip>45061</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Poznan</city>
        <zip>60631</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Rzeszow</city>
        <zip>35055</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02106</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Barcelona</city>
        <zip>8908</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Barcelona</city>
        <zip>8916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Bournemouth</city>
        <zip>BH77DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>London</city>
        <zip>W1G 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MorphoSys Research Site</name>
      <address>
        <city>Newcastle</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2015</study_first_submitted>
  <study_first_submitted_qc>March 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2015</study_first_posted>
  <last_update_submitted>December 5, 2017</last_update_submitted>
  <last_update_submitted_qc>December 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DLBCL</keyword>
  <keyword>CD19</keyword>
  <keyword>monoclonal antibody</keyword>
  <keyword>MOR00208</keyword>
  <keyword>MOR208</keyword>
  <keyword>lenalidomide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

